pricing-dollar
  • Home
  • » 
  • Reports
  • » 
  • Bispecific Antibodies Clinical Trials

Bispecific Antibodies Clinical Trials

Bispecific Antibodies: Clinical Trial Tracker

  • Lowest Price Guaranteed

  • Slides
    Not Available

  • Last Updated
    October 2023

  • View Count
    10873

Analyze with AI

ChatGPT Perplexity Claude Google AI

Bispecific Antibodies Overview

Bispecific antibodies (bsAbs) are artificial antibodies created by joining together two monoclonal antibodies (or parts) that target different epitopes.The resulting antibody has binding affinities for two or three different epitopes concurrently.

Various technology platforms have been used for bsAbs production over the years. These platforms are based on the concepts of chemical crosslinking, hybrid hybridomas, with the latest being recombinant techniques. Different binding sites can be exploited to produce bispecific systems with different mechanisms, such as the T cell engager system. As of now, only two bsAbs, Removab and Blincyto, have been approved and are available in the market. The focus of the pipeline drugs is on oncology as well as on non-oncological indications such as rheumatoid arthritis and other inflammatory diseases.

Recent Developments in Bispecific Antibodies Market:

Several recent developments have taken place in the field of bispecific antibodies. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In April 2023, Lonza entered into a collaboration with ABL Bio with an aim to support the development and manufacturing of ABL Bio’s new bispecific antibody product. 
  • In February 2023, Atreca entered into a collaboration with Xencor in order to develop T cell engaging bispecific antibody directed against novel solid tumor target.

Scope of the Report

The primary objective of this report is to capture details on the various clinical and preclinical trials which are currently underway in the field of bsAb therapeutics.We have identified a number of such trials which are taking place for a variety of indications across multiple geographies.For each specific trial, we have provided the following information:

  1. Trial Objective

  2. Manufacturer /Licensee

  3. Technology

  4. Target Antigen

  5. Indication

  6. Sponsor / Collaborator

  7. Trial Phase

  8. Trial Status

  9. Start Date

  10. End Date

  11. Enrolment

  12. AgeGroup

  13. Inclusion Criteria

  14. Exclusion Criteria

  15. StudyDesign

  16. PrimaryEndpoint

  17. SecondaryEndpoint

  18. Treatment Arms

  19. Route ofAdministration

  20. Location(s)

  21. Trial Results (if known)

The above information has also been presented in the form a dashboard to provide a high level quick overview of the ongoing activity in this space.

In addition to the clinical trial details, the report also provides the following:

  • Sales forecasts of the bispecific antibody market over the course of next ten years. Owing to the niche nature of this market, we have presented three scenarios to add robustness to our market forecast. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.

  • Industry SWOT analysis summarising the challenges as well as opportunities in the market for different stakeholders.

Download Free Sample